NCT04780347Unknown2 期
A Phase II, Single-center, Randomized Study of Albumin-bound Paclitaxel Combination With Capecitabine Versus Capecitabine Monotherapy in Paclitaxel/Docetaxel-resistant Advanced Breast Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 入组人数
- 92
- 试验地点
- 1
- 主要终点
- PFS
研究概览
简要总结
Albumin-bound Paclitaxel Combination With Capecitabine Versus Capecitabine Monotherapy in Paclitaxel/Docetaxel-resistant Advanced Breast Cancer
详细描述
A Phase II, single-center, randomized study of albumin-bound paclitaxel combination with capecitabine versus capecitabine monotherapy in paclitaxel/docetaxel-resistant advanced breast cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Females with age between 18 and 70 years old
- •Histological proven unresectable recurrent or advanced breast cancer
- •Negative for human epithelial receptor-2 (HER2) by immunohistochemistry. A negative Her2 gene amplification should be verified by FISH test for those patients with Her2 (2+). For those with Her2 (1+), FISH test might be considered by the investigator.
- •Patients who developed disease progression within 12 months of previous paclitaxel-containing chemotherapy regimens.
- •At least one measurable disease according to the response evaluation criteria in solid tumor (RECIST 1.1)
- •Performance status no more than 1
- •All patients enrolled are required to have adequate hematologic, hepatic, and renal function
- •Life expectancy longer than 12 weeks
- •No serious medical history of heart, lung, liver and kidney
- •Be able to understand the study procedures and sign informed consent.
- •Patients with good compliance.
排除标准
- •Pregnant or lactating women (female patients of child-bearing potential must have a negative serum pregnancy test within 14 days before the first day of drug dosing, or, if positive, a pregnancy should be ruled out by ultrasound)
- •Women of child-bearing potential, unwilling to use adequate contraceptive protection during the process of the study
- •Treatment with radiotherapy at the axial skeleton within 4 weeks before the first treatment or has not recovered from all toxicities of previous radiotherapy
- •Treatment with an investigational product within 4 weeks before the first treatment
- •Patients with symptomatic central nervous system metastases are not permitted, except for those with stable and asymptomatic brain metastases who have completed cranial irradiation, and have at least one measurable lesion outside the brain. Radiotherapy should be completed within 4 weeks prior to the registration
- •Other active malignancies (including other hematologic malignancies) or other malignancies within the last 5 years, except for cured nonmelanoma skin cancer or cervical intraepithelial neoplasia.
- •Patients having a history of clinically significant cardiovascular, hepatic, respiratory or renal diseases, clinically significant hematological and endocrinal abnormalities, clinically significant neurological or psychiatric conditions
- •Uncontrolled serious infection
研究组 & 干预措施
Albumin-bound paclitaxel plus capecitabine
Experimental
Albumin-bound paclitaxel combined with capecitabine
干预措施: Albumin-bound paclitaxel plus capecitabine (Drug)
Capecitabine
Active Comparator
Capecitabine
干预措施: capecitabine (Drug)
结局指标
主要结局
PFS
时间窗: approximately 6 weeks
Progression Free Survival
次要结局
- ORR(approximately 6 weeks)
- OS(Up to approximately 30 months)
研究者
Jian Zhang,MD
Chief physician
Fudan University
研究点 (1)
Loading locations...
相似试验
已完成
2 期
A Phase II Study of Capecitabine plus Paclitaxel Combination Chemotherapy in Patients with Metastatic Breast CancerMetastatic Breast CancerJPRN-UMIN000000869KBCSG (Kinki Breast Cancer Study Group)42
Unknown
2 期
Combined Simvastatin and Albumin Paclitaxel in Treating ES-SCLC Patients Relapsed From 1st ChemotherapySmall Cell Lung CancerNCT04698941Shanghai Pulmonary Hospital, Shanghai, China40
Unknown
2 期
Comparison Study of Neoadjuvant Paclitaxel Plus Carboplatin/Epirubicin Treatment in Triple-negative Breast CancerTriple Negative Breast CancerNCT01276769Chinese Academy of Medical Sciences80
撤回
不适用
Nab-paclitaxel Based Regimens VS Paclitaxel Based Regimens in Neoadjuvant Treatment for TNBCTriple Negative Breast CancerNCT04067102Hebei Medical University Fourth Hospital
已完成
2 期
Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)Cancer of the BreastEstrogen Receptor- Negative Breast CancerHER2- Negative Breast CancerProgesterone Receptor- Negative Breast CancerRecurrent Breast CancerStage IV Breast CancerTriple-negative Metastatic Breast CancerMetastatic Breast CancerTriple-negative Breast CancerBreast CancerBreast TumorNCT01881230Celgene191